NewAmsterdam Pharma Company NV
NAMS21.370USD
+0.090+0.42%
시장 운영 시간 （ET）시세는 15분 지연됩니다
2.40B시가총액
손실P/E TTM
자세한 내용은 NewAmsterdam Pharma Company NV 회사
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
회사 정보
종목 코드 NAMS
회사 이름NewAmsterdam Pharma Company NV
상장일Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
직원 수68
유형Ordinary Share
회계 연도 종료Nov 23
주소Gooimeer 2-35
도시NAARDEN
증권 거래소NASDAQ Global Market Consolidated
국가Netherlands
우편 번호1411 DC
전화31352062971
웹사이트https://ir.newamsterdampharma.com/
종목 코드 NAMS
상장일Nov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Thu, Jul 24
마지막 업데이트: Thu, Jul 24
주주
주주 유형
주주
주주
비율
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
주주
주주
비율
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
주주 유형
주주
비율
Investment Advisor
35.92%
Investment Advisor/Hedge Fund
23.68%
Venture Capital
21.76%
Private Equity
14.36%
Hedge Fund
13.18%
Research Firm
1.42%
Family Office
0.71%
Individual Investor
0.45%
Bank and Trust
0.28%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
262
128.82M
114.74%
+5.59M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
2023Q1
105
62.44M
76.40%
-1.21M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Frazier Life Sciences Management, L.P.
16.12M
14.36%
+200.00K
+1.26%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.55%
--
--
Mar 31, 2025
Forbion Capital Partners
10.66M
9.49%
-279.14K
-2.55%
Apr 15, 2025
Capital Research Global Investors
8.83M
7.86%
--
--
May 31, 2025
RA Capital Management, LP
10.14M
9.03%
+1.29M
+14.63%
Mar 31, 2025
Viking Global Investors LP
6.98M
6.22%
--
--
Mar 31, 2025
Capital World Investors
6.80M
6.06%
+5.78M
+569.10%
Mar 31, 2025
Deerfield Management Company, L.P.
4.10M
3.66%
-210.38K
-4.88%
Mar 31, 2025
Wellington Management Company, LLP
3.54M
3.15%
+1.23M
+52.99%
Mar 31, 2025
Jennison Associates LLC
3.97M
3.54%
-28.35K
-0.71%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
ALPS Medical Breakthroughs ETF
1.38%
Global X Guru Index ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.29%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
iShares Biotechnology ETF
0.12%
First Trust Small Cap Core Alphadex Fund
0.11%
First Trust IPOX Europe Equity Opportunities ETF
0.09%
더 보기
ALPS Medical Breakthroughs ETF
비율1.38%
Global X Guru Index ETF
비율1.17%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.35%
First Trust Small Cap Growth AlphaDEX Fund
비율0.29%
ProShares Ultra Nasdaq Biotechnology
비율0.23%
Invesco Nasdaq Biotechnology ETF
비율0.23%
iShares Biotechnology ETF
비율0.12%
First Trust Small Cap Core Alphadex Fund
비율0.11%
First Trust IPOX Europe Equity Opportunities ETF
비율0.09%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
